These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7744191)

  • 1. One month treatment with the once daily oral beta 2-agonist bambuterol in asthmatic patients.
    Persson G; Baas A; Knight A; Larsen B; Olsson H
    Eur Respir J; 1995 Jan; 8(1):34-9. PubMed ID: 7744191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study using oral solutions of bambuterol once daily or terbutaline three times daily in 2-5-year-old children with asthma. Bambuterol Multicentre Study Group.
    Kuusela AL; Marenk M; Sandahl G; Sanderud J; Nikolajev K; Persson B
    Pediatr Pulmonol; 2000 Mar; 29(3):194-201. PubMed ID: 10686040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration.
    D'Alonzo GE; Smolensky MH; Feldman S; Gnosspelius Y; Karlsson K
    Chest; 1995 Feb; 107(2):406-12. PubMed ID: 7842769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic equivalence between bambuterol, 10 mg once daily, and terbutaline controlled release, 5 mg twice daily, in mild to moderate asthma.
    Fugleholm AM; Ibsen TB; Laxmyr L; Svendsen UG
    Eur Respir J; 1993 Nov; 6(10):1474-8. PubMed ID: 8112441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids.
    Crompton GK; Ayres JG; Basran G; Schiraldi G; Brusasco V; Eivindson A; Jamieson AH; Olsson H
    Am J Respir Crit Care Med; 1999 Mar; 159(3):824-8. PubMed ID: 10051257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of two long-acting beta-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms. The French Bambuterol Study Group.
    Wallaert B; Brun P; Ostinelli J; Murciano D; Champel F; Blaive B; Montané F; Godard P
    Respir Med; 1999 Jan; 93(1):33-8. PubMed ID: 10464846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between a new once-daily, bronchodilating drug, bambuterol, and terbutaline sustained-release, twice daily.
    Persson G; Gnosspelius Y; Anehus S
    Eur Respir J; 1988 Mar; 1(3):223-6. PubMed ID: 3384075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators.
    van der Molen T; Postma DS; Turner MO; Jong BM; Malo JL; Chapman K; Grossman R; de Graaff CS; Riemersma RA; Sears MR
    Thorax; 1997 Jun; 52(6):535-9. PubMed ID: 9227720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year safety study with bambuterol once daily and terbutaline three times daily in 2-12-year-old children with asthma. The Bambuterol Multicentre Study Group.
    Zarkovic JP; Marenk M; Valovirta E; Kuusela AL; Sandahl G; Persson B; Olsson H
    Pediatr Pulmonol; 2000 Jun; 29(6):424-9. PubMed ID: 10821722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H; Orozco S; Allen A
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A placebo-controlled dose-finding study with bambuterol in elderly patients with asthma.
    Sitar DS; Aoki FY; Warren CP; Knight A; Grossman RF; Alexander M; Soliman S
    Chest; 1993 Mar; 103(3):771-6. PubMed ID: 8449067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of oral bambuterol and terbutaline in elderly patients with chronic reversible airflow obstruction.
    McDonald CF; Pierce RJ; Thompson PJ; Allen D; Bowler S; Breslin AB; Bowes G; Saunders N; Murree-Allen K; Frith P; Musk AW
    J Asthma; 1997; 34(1):53-9. PubMed ID: 9033440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rebound airway obstruction and responsiveness after cessation of terbutaline: effects of budesonide.
    de Jong JW; van der Mark TW; Koëter GH; Postma DS
    Am J Respir Crit Care Med; 1996 Jan; 153(1):70-5. PubMed ID: 8542165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment.
    Hancox RJ; Cowan JO; Flannery EM; Herbison GP; McLachlan CR; Taylor DR
    Respir Med; 2000 Aug; 94(8):767-71. PubMed ID: 10955752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma. ACROBATICS Research Group.
    Gunn SD; Ayres JG; McConchie SM
    Eur J Clin Pharmacol; 1995; 48(1):23-8. PubMed ID: 7621843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 3-month comparison of formoterol with terbutaline via turbuhaler. A placebo-controlled study.
    Ekström T; Ringdal N; Tukiainen P; Runnerström E; Soliman S
    Ann Allergy Asthma Immunol; 1998 Sep; 81(3):225-30. PubMed ID: 9759798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
    D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
    JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can a new beta 2-agonist reduce the mortality of asthma?
    Aldons PM
    Lung; 1990; 168 Suppl():186-91. PubMed ID: 1974675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bambuterol: effective in nocturnal asthma.
    Petrie GR; Chookang JY; Hassan WU; Morrison JF; O'Reilly JF; Pearson SB; Shneerson JM; Tang OT; Ning AC; Turbitt ML
    Respir Med; 1993 Nov; 87(8):581-5. PubMed ID: 8290741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose formoterol Turbuhaler (Oxis) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.).
    Ekström T; Ringdal N; Sobradillo V; Runnerström E; Soliman S
    Respir Med; 1998 Aug; 92(8):1040-5. PubMed ID: 9893773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.